66
Participants
Start Date
June 4, 2015
Primary Completion Date
February 6, 2019
Study Completion Date
July 4, 2019
Blinatumomab
Continuous intravenous infusion over four weeks per treatment cycle
National Hospital Organization Nagoya Medical Center, Nagoya
Nagoya University Hospital, Nagoya
Kyushu University Hospital, Fukuoka
Gunmaken Saiseikai Maebashi Hospital, Maebashi
Sapporo Hokuyu Hospital, Sapporo
Kobe University Hospital, Kobe
Kanagawa Childrens Medical Center, Yokohama
Nagasaki University Hospital, Nagasaki
Niigata Cancer Center Hospital, Niigata
Okayama University Hospital, Okayama
Osaka City General Hospital, Osaka
Osaka Metropolitan University Hospital, Osaka
Saitama Childrens Medical Center, Saitama-shi
Jichi Medical University Hospital, Shimotsuke-shi
National Cancer Center Hospital, Chuo-ku
National Center for Child Health and Development, Setagaya-ku
Lead Sponsor
Amgen Astellas Biopharma K.K.
INDUSTRY
Amgen
INDUSTRY